País: Canadà
Idioma: anglès
Font: Health Canada
PRALSETINIB
HOFFMANN-LA ROCHE LIMITED
L01EX23
PRALSETINIB
100MG
CAPSULE
PRALSETINIB 100MG
ORAL
15G/50G
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0163030001; AHFS:
APPROVED
2021-06-30
_Pr_ _GAVRETO™(pralsetinib) _ _Page 1 of 40_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR GAVRETO™ pralsetinib capsules Capsules, 100 mg pralsetinib, Oral Protein Kinase Inhibitor (L01EX) GAVRETO, indicated for: the treatment of adult patients with rearranged during transfection (_RET_) fusion-positive locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC). has been issued market authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for GAVRETO please refer to Health Canada’s Notice of Compliance with conditions - drug products web site: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice- compliance/conditions.html” Hoffmann-La Roche Limited 7070 Mississauga Road Mississauga, Ontario, Canada L5N 5M8 Date of Initial Authorization: June 30, 2021 Submission Control Number: 243731 GAVRETO™ is a trade-mark of Blueprint Medicines Corporation, used under license. © Copyright 2021, Hoffmann-La Roche Limited _ _ _Pr_ _GAVRETO™(pralsetinib) _ _Page 2 of 40_ WHAT IS A NOTICE OF COMPLIANCE WITH CONDITIONS (NOC/C)? _An NOC/c is a form of market approval granted to a product on the basis of promising evidence _ _of clinical effectiveness following review of the submission by Health Canada. _ _Products authorized under Health Canada’s NOC/c policy are intended for the treatment, _ _prevention or diagnosis of a serious, life-threatening or severely debilitating illness. They have _ _demonstrated promising benefit, are of high quality and possess an acceptable safety profile _ _based on a benefit/risk assessment. In addition, they either respond to a serious unmet medical _ _need in Canada or have demonstrated a significant improvement in the benefit/risk profile over _ _existing therapies. Health Canada has provided access to this product on the condition that _ _sponsors carry out additional clinical trial Llegiu el document complet